null

Talacotuzumab (Anti-CD123) Biosimilar Antibody

SKU:
HDBS0003
Product Type:
Biosimilar Antibody
Antibody Type:
Monoclonal Antibody
Protein:
CD123
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
  • Anti-CD123 talacotuzumab biosimilar mAb HDBS0003
  • Anti-CD123 talacotuzumab biosimilar mAb HDBS0003
  • Anti-CD123 talacotuzumab biosimilar mAb HDBS0003
€373
Frequently bought together:

Description

system_update_altDatasheet

Talacotuzumab (Anti-CD123) Biosimilar Antibody (HDBS0003)

The Anti-CD123 Talacotuzumab Biosimilar MAB (HDBS0003) is a groundbreaking monoclonal antibody targeting CD123, a protein overexpressed in certain leukemic cells, with potential applications in cancer treatment. Talacotuzumab, a biosimilar of a well-known therapeutic antibody, has been engineered to specifically bind to CD123, inhibiting its function and potentially disrupting the growth and survival of cancer cells.This antibody, developed using advanced biotechnological methods, has shown high specificity and potency in preclinical studies, making it a promising candidate for targeted cancer therapy. By targeting CD123, which is highly expressed in leukemia and other hematologic malignancies, talacotuzumab offers a novel approach to treatment that may enhance the efficacy and reduce the side effects of traditional chemotherapy.

The Anti-CD123 Talacotuzumab Biosimilar MAB (HDBS0003) represents a new weapon in the fight against cancer, with the potential to revolutionize treatment strategies and improve outcomes for patients with CD123-expressing cancers. Its development opens up exciting possibilities for personalized medicine and precision oncology, offering hope for those facing the challenges of this devastating disease.